-
03:30:54 AM

CSLLY Stock News

03/27/23 3:30 PM
OTC : CSLLY
CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
The custom-built facility is approximately 140,000 square feet with 54,000 square feet of lab space, including the first biosafety level 3 laboratory in Waltham. "CSL's growing R&D presence in Waltham is the latest example of our investment in our future– which includes advancing our growing capabilities in disruptive technologies like next-generation...
RHEA-AI
very positive
02/26/23 10:45 AM
OTC : CSLLY
clinical trial
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Global biotechnology leader CSL today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab. The data were presented during the 2023 American Academy of Allergy Asthma& Immunology Annual Meeting, February 24-27, in San Antonio, Texas. Timothy Craig, Tenured Professor of Medicine, Pediatrics and Biomedical...
RHEA-AI
neutral
02/23/23 8:00 AM
OTC, Nasdaq : CSLLY, QURE
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion 18-month data support the efficacy
RHEA-AI
neutral